Author Archives: Jose Marques Lopes PhD

Adding Darzalex to a Velcade-Revlimid Combo Boosts Cancer Disappearance in Newly Diagnosed Multiple Myeloma, Phase 2 Trial Shows

Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing complete cancer disappearance, according to top-line results of a Phase 2 clinical trial. The open-label GRIFFIN study (NCT02874742) includes 223 patients eligible for high-dose…

Empliciti Combo Prolongs Survival in Difficult-to-Treat Multiple Myeloma, New Phase 2 Trial Data Show

Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease progression in patients with relapsed or refractory multiple myeloma, according to updated results of a Phase 2 study. The study, “Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory…